Dianthus Therapeutics (DNTH) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 144.6% versus a loss of 1.1%. Over five years, PTCT leads with a +66.0% price change compared with -21.2% for DNTH. PTC Therapeutics is the larger company by market cap ($5.28 billion vs $4.75 billion), about 1.1 times the size.
PTC Therapeutics converts more of its revenue into profit, with a net margin of 39.4% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | PTCT |
|---|---|---|
| Share price | $84.88 | $63.23 |
| Market cap | $4.75B | $5.28B |
| 1-day change | -0.61% | -0.74% |
| YTD return | +105.97% | -16.76% |
| 1-year return | +144.61% | -1.06% |
| 5-year return | -21.17% | +66.00% |
| Forward P/E | — | 23.62 |
| EPS (TTM) | $-4.24 | $-0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $1.73B |
| Revenue growth (YoY) | -67.35% | +114.51% |
| Net income (latest FY) | $-162.34M | $682.64M |
| Operating margin | -8739.34% | 50.09% |
| Net margin | -7973.33% | 39.44% |
| 52-week high | $117.88 | $90.87 |
| 52-week low | $32.22 | $61.23 |
| Distance from 52-week high | -27.99% | -30.42% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +65.88% | +60.98% |
| Average volume | 825.33K | 1.15M |
| Shares outstanding | 55.93M | 83.46M |
| Employees | 92 | 991 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed PTCT by 145.7 percentage points over the past year.
- PTC Therapeutics is more profitable, keeping 39.4 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- PTC Therapeutics grew revenue faster in its latest fiscal year (+114.51% vs -67.35%).
- The two companies sit in different sectors: Dianthus Therapeutics in Healthcare and PTC Therapeutics in Health Care.
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Healthcare · Biotechnology · 92 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
DNTH vs PTCT FAQ
Which is bigger, Dianthus Therapeutics or PTC Therapeutics?
PTC Therapeutics (PTCT) is larger, with a market capitalization of $5.28B compared with $4.75B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, DNTH or PTCT?
DNTH returned +144.61% over the past 12 months, compared with -1.06% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and PTC Therapeutics in the same industry?
No. Dianthus Therapeutics is in the Healthcare sector, while PTC Therapeutics is in Health Care.